API | peginterferon beta-1a

peginterferon beta-1a (Plegridy) Report issue

Biologics Recombinant protein Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW

Now

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
peginterferon beta-1a

More Chemistry

Pharmacology

Mechanisms of Action:
- Interferon alpha/beta receptor 1 (Homo sapiens) ^UniProt
- Interferon alpha/beta receptor 2 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

Australia

$367.1627

United States

$2557.9500 - $3447.5700

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

biib017 | peg ifn-beta-1a | peginterferon beta-1a | pegylated interferon beta-1a | plegridy | polyethylene glycol-interferon beta-1a | polyethylene glycol-interferon-beta-1a

Organizations (69)

Research & Development (67)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (22)

Approved Indications (1)

Multiple Sclerosis

Experimental Indications - Clinical Trial Phases 1-4 (22)

Acute Lung Injury (Phase 1/Phase 2)

Astrocytoma (Phase 1)

Carcinoma, Merkel Cell (Phase 1/Phase 2)

Coronavirus Infections (Phase 3)

COVID-19 (Phase 4)

Glioblastoma (Phase 1)

Gliosarcoma (Phase 1)

Healthy Volunteers (Phase 1)

Hepatitis C, Chronic (Phase 3)

Interferons (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 4)

Macular Edema (Phase 3)

Melanoma (Phase 2)

Multiple Sclerosis ()

Multiple Sclerosis, Chronic Progressive (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Pharmacokinetics (Phase 1)

Renal Insufficiency (Phase 1)

Respiratory Distress Syndrome (Phase 1/Phase 2)

Severe Acute Respiratory Syndrome (Phase 3)

Therapeutic Equivalency (Phase 1)

Uveitis, Intermediate (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 55
# of Trial Organizations: 67

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue